Shionogi & Co (4507) investor relations material

Executive summary

• Achieved record-high first-quarter revenue and profit, driven by growth in existing businesses, integration of acquired businesses, and expanded overseas sales and royalties.

• Revenue for Q1 FY2026 reached ¥163.3 billion, up 63.7% year-over-year, marking a record high for the first quarter.

• Operating profit rose 90.6% year-over-year to ¥66.9 billion, and profit attributable to owners of parent surged 148.2% to ¥97.7 billion.

• Growth was driven by consolidation of Torii Pharmaceutical, acquisition of the edaravone business, and expanded overseas sales and royalties.

Financial highlights

• Revenue for 1Q FY2026 was ¥163.3B, up 63.7% year-over-year.

• Operating profit reached ¥66.9B, up 90.6% year-over-year.

• Profit attributable to owners of parent was ¥97.7B, up 148.2% year-over-year.

• EBITDA was ¥93.4B, up 129.8% year-over-year.

• Gross profit increased to ¥132.5B from ¥87.5B year-over-year.

Outlook and guidance

• On track to achieve 1H forecast, with continued investment in U.S. business and further growth expected from HIV franchise and overseas operations.

• No revisions to the consolidated financial forecast for FY2027; full-year revenue forecast at ¥700B and profit attributable to owners of parent at ¥220B.

• Basic earnings per share forecast for the year is ¥246.79.

• From Q2, PPA impacts from increased ViiV shareholding will be reflected in equity method income.